XML 57 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Stock Based Compensation (Tables)
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation Expense The following table summarizes the stock-based compensation expense recognized under all of the Company's stock plans in 2020, 2019, and 2018 and associated with the issuance of restricted shares of common stock and vesting of stock options which
are included in General and administrative expenses in the accompanying consolidated statement of income recognized (in thousands):
Years ended December 31,
20202019            2018
Stock options$1,763 $688 $— 
Restricted stock awards1,620 252 632 
APC stock options— 607 810 
Total share-based compensation expense$3,383 $1,547 $1,442 
Schedule of Stock Option Transactions Under Stock Option Plans
The Company’s outstanding stock options consisted of the following:
SharesWeighted
Average
Exercise Price
Weighted
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
(in millions)
Options outstanding at January 1, 2020607,346 $9.22 3.42$5.6 
Options granted250,746 18.11 — — 
Options exercised(120,000)2.58 — 1.8 
Options canceled, forfeited or expired(12,228)17.57 — — 
Options outstanding at December 31, 2020725,864 $13.25 3.75$3.4 
Options exercisable at December 31, 2020449,464 $6.33 1.94$3.6 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
During the year ended December 31, 2020, the Company granted 191,742 and 59,004 five-year stock options to certain ApolloMed board members and executives, respectively, with exercise price ranging from $18.20-$18.41 and $17.78, respectively, which were recognized at fair value, as determined using the Black-Scholes option pricing model as follows:
December 31, 2020Board MembersExecutives
Expected Term3.0 years3.5 years
Expected volatility
85.44% - 90.01%
80.95 %
Risk-free interest rate
0.23% - 1.43%
0.23 %
Market value of common stock
$18.20 - $18.41
$ 17.78
Annual dividend yield%%
Forfeiture rate%%